International Assets Investment Management LLC Boosts Stake in Natera, Inc. (NASDAQ:NTRA)

International Assets Investment Management LLC increased its position in Natera, Inc. (NASDAQ:NTRA) by 6,007.5% in the 4th quarter, according to its most recent filing with the SEC. The fund owned 7,329 shares of the medical research company’s stock after purchasing an additional 7,209 shares during the period. International Assets Investment Management LLC’s holdings in Natera were worth $459,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in NTRA. CWM LLC increased its position in Natera by 224.4% in the 3rd quarter. CWM LLC now owns 1,317 shares of the medical research company’s stock valued at $58,000 after acquiring an additional 911 shares during the period. Ellsworth Advisors LLC acquired a new position in Natera in the 3rd quarter valued at about $364,000. Xponance Inc. increased its position in Natera by 1.8% in the 3rd quarter. Xponance Inc. now owns 14,506 shares of the medical research company’s stock valued at $642,000 after acquiring an additional 261 shares during the period. Brown Advisory Inc. increased its position in Natera by 9.2% in the 3rd quarter. Brown Advisory Inc. now owns 4,738 shares of the medical research company’s stock valued at $210,000 after acquiring an additional 400 shares during the period. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in Natera by 19.6% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 20,616 shares of the medical research company’s stock valued at $912,000 after acquiring an additional 3,384 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Insider Buying and Selling

In related news, CEO Steven Leonard Chapman sold 14,813 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The stock was sold at an average price of $65.09, for a total value of $964,178.17. Following the sale, the chief executive officer now owns 246,957 shares of the company’s stock, valued at approximately $16,074,431.13. The transaction was disclosed in a filing with the SEC, which is available through this link. In related news, Director Herm Rosenman sold 93,901 shares of the company’s stock in a transaction that occurred on Friday, February 16th. The stock was sold at an average price of $69.37, for a total value of $6,513,912.37. Following the sale, the director now owns 61,685 shares of the company’s stock, valued at approximately $4,279,088.45. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, CEO Steven Leonard Chapman sold 14,813 shares of the company’s stock in a transaction that occurred on Monday, January 29th. The shares were sold at an average price of $65.09, for a total value of $964,178.17. Following the completion of the sale, the chief executive officer now directly owns 246,957 shares in the company, valued at approximately $16,074,431.13. The disclosure for this sale can be found here. Insiders have sold a total of 453,644 shares of company stock worth $36,594,940 in the last quarter. Company insiders own 9.42% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on NTRA. Sanford C. Bernstein upgraded Natera from a “market perform” rating to an “outperform” rating and set a $120.00 price target on the stock in a research report on Friday, April 5th. The Goldman Sachs Group boosted their price target on Natera from $90.00 to $100.00 and gave the company a “buy” rating in a research report on Monday, April 15th. Craig Hallum started coverage on Natera in a research report on Monday, April 8th. They set a “buy” rating and a $117.00 target price on the stock. StockNews.com cut Natera from a “hold” rating to a “sell” rating in a research report on Tuesday. Finally, Canaccord Genuity Group boosted their target price on Natera from $87.00 to $100.00 and gave the stock a “buy” rating in a research report on Thursday, February 29th. One equities research analyst has rated the stock with a sell rating and fourteen have given a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $86.40.

Natera Stock Performance

NTRA opened at $91.28 on Friday. The stock has a market cap of $11.02 billion, a P/E ratio of -24.08 and a beta of 1.37. The company has a debt-to-equity ratio of 0.37, a current ratio of 4.10 and a quick ratio of 3.96. The stock’s 50 day simple moving average is $87.29 and its 200 day simple moving average is $67.00. Natera, Inc. has a 1-year low of $36.90 and a 1-year high of $98.82.

Natera (NASDAQ:NTRA) last released its quarterly earnings results on Wednesday, February 28th. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.73) by $0.09. The business had revenue of $311.11 million for the quarter, compared to analysts’ expectations of $300.38 million. Natera had a negative return on equity of 62.19% and a negative net margin of 40.16%. As a group, equities analysts anticipate that Natera, Inc. will post -2.35 EPS for the current fiscal year.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.